Startups

Senior Director, Global Commercial Development, Early Detection & Market Shaping

Revolution Medicines · Remote (United States) · Remote

← All jobs
About Revolution Medicines

Backed by GV.

About the role

Reporting to the Executive Director, Early Stage, Global Commercial Development – Pancreatic Cancer, this role will lead the global commercial strategy to enable earlier identification and diagnosis of pancreatic cancer. The Senior Director will shape the future early-detection ecosystem—connecting science, screening and surveillance pathways, diagnostic innovation, healthcare delivery, and disease education—with Revolution Medicines’ longer-term early-stage portfolio ambitions. Found on 1752vc Careers, the job board for startup and VC roles.

What they're looking for

  • Bachelor’s degree with at least 15 years, or advanced degree with at least 8 years, of progressive commercial experience in a biotechnology and/or pharmaceutical company, including strategic marketing and ideally sales
  • Proven success developing and executing global commercial strategy and influencing cross-functional product or disease-area teams
  • Demonstrated ability to derive actionable insights and analytics that inform innovative commercial strategies and investment decisions
  • Strong leadership, with the ability to lead teams, collaborate effectively across functions, and influence without direct authority
  • Excellent organizational skills and ability to prioritize effectively and deliver results within established timelines
  • Strong clinical and scientific acumen, ability to translate preclinical and clinical data into commercial implications
More about this role

Revolution Medicines is a global, commercial-state oncology company dedicated to discovering, developing and delivering innovative medicines for patients with RAS-addicted cancers. Leveraging its differentiated RAS(ON) tri-complex inhibitor platform, the company is advancing a broad, integrated portfolio of oral RAS(ON) inhibitors designed to directly target the active, cancer-driving state of RAS. Founded on rigorous scientific inquiry and a willingness to challenge long-held assumptions, Revolution Medicines is committed to changing the trajectory of disease for patients with RAS-addicted cancers worldwide.

Our people are united by a shared way of working: follow the science, challenge assumptions, act with urgency and hold ourselves to a high standard of rigor—all in service of patients.

Reporting to the Executive Director, Early Stage, Global Commercial Development – Pancreatic Cancer, this role will lead the global commercial strategy to enable earlier identification and diagnosis of pancreatic cancer. The Senior Director will shape the future early-detection ecosystem—connecting science, screening and surveillance pathways, diagnostic innovation, healthcare delivery, and...

Read the full posting on Revolution Medicines's site ↗

Global Commercial Development

Build your edge while you search

Free tools for founders and investors, plus VC Unfiltered, our take on startups, venture and the people who build them.